convalescent plasma treatment - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.79 [0.49, 1.29]< 10%6 studies (6/-)82.3 %some concernnot evaluable moderatecrucial-
deaths (time to event analysis only) 0.93 [0.47, 1.85]< 10%1 study (1/-)58.2 %lownot evaluable highcrucial-
clinical deterioration 0.48 [0.28, 0.83]< 10%2 studies (2/-)99.6 %some concernnot evaluable moderateimportant-
clinical improvement 0.99 [0.73, 1.33]> 15%3 studies (3/-)46.7 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.42 [0.65, 3.10]> 10%1 study (1/-)81.1 %some concernnot evaluable moderateimportant-
death or ventilation 0.67 [0.14, 3.26]< 10%1 study (1/-)69.0 %lownot evaluable highimportant-
ventilation 1.12 [0.28, 4.47]< 140%2 studies (2/-)43.9 %some concernnot evaluable moderateimportant-
ICU admission 0.33 [0.07, 1.58]< 10%1 study (1/-)91.7 %lownot evaluable highnon important-

safety endpoints 00

serious adverse events 1.30 [0.77, 2.20]< 10%2 studies (2/-)16.2 %some concernnot evaluable moderateimportant-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.